Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
|Videos|August 6, 2014
Strategies for Overcoming <em>KRAS</em> Mutations in Lung Cancer
Author(s)David Gandara, MD
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcoming KRAS mutations in lung cancer.
Advertisement
Clinical Pearls
David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center, discusses overcomingKRASmutations in lung cancer. Gandara presented on this topic at the
- KRASmutations tend to predict less response to chemotherapy or TKIs.
- It has been extremely difficult to develop drugs that directly inhibit KRAS.
- MEK inhibitors in combination with chemotherapy have shown downstream activity.
- SWOG 1408 will test this hypothesis with a MEK inhibitor (trametinib) in combination with chemotherapy (docetaxel) or an AKT inhibitor (GSK795).
Advertisement
Related to this article
The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
Osimertinib was associated with a 47% reduction in risk of death among patients with stage II-IIIA EGFR-mutated non–small cell lung cancer at 8 years.
A single blood draw 3 to 9 weeks into immunotherapy predicted survival outcomes in metastatic non–small cell lung cancer, according to a new Johns Hopkins study.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.
First-line amivantamab plus chemotherapy produced the longest reported median OS in EGFR exon 20 insertion-positive advanced NSCLC in the phase 3 PAPILLON trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
A Look Inside CONVERGE: Intratumoral Therapy Comes to Locally Advanced NSCLC
2
DiBardino Outlines Phase 2 CONVERGE Trial Design of Radioenhancer in NSCLC
3
FDA Approves Imlunestrant Plus Abemaciclib in ESR1-Mutated Breast Cancer
4
Taletrectinib Sustains Durable ROS1+ NSCLC Responses at 3-Year Follow-Up
5